A primary public stock offering of 2 million common shares has been announced by Centogene in hopes of raising $28 million in gross proceeds. A secondary offering of 1.5 million common shares from selling shareholders aims to raise $21 million.
The FDA has given 510(k) clearance to Infervision for its InferRead Lung CT.AI system, an artificial intelligence-run system that automatically labels and identifies different types of lung nodules during CT scan reviews.
ApiJect Systems America, a small medical device maker, has been granted a $138 million no-bid contract by the Defense Department to produce 100 million of its injector that has not yet been approved by the FDA. An additional $456 million was offered to the company through a public-private partnership for the construction of several new factories to manufacture an additional 500 million devices.
Federal approval of Pfizer's coronavirus vaccine could happen in October, says CEO Albert Bourla as the company plans to begin manufacturing ahead of such approval. "We should be able in the September time frame to have enough data to say if the vaccine works or not. And to submit that to the FDA," Bourla said.
Freeline will advance the launch of its pivotal clinical trial for its gene therapy candidate FLT180a as a treatment for hemophilia B with the $120 million it raised from an extended Series C funding round. The proceeds will also support ongoing trials for FLT190 to treat Fabry disease and the development of gene therapy candidates FLT200/201 for Gaucher disease and FLT210 for hemophilia A.
Scientists have developed spider silk using Rhodovulum sulfidophilum, a marine photosynthetic purple bacterium, according to research published in the journal Communications Biology. The biocompatibility of this type of spider silk "makes it safe for use in biomedical applications such as drug delivery systems, implant devices, and scaffolds for tissue engineering," said study author Choon Pin Foong.
White House Chief of Staff Mark Meadows said President Donald Trump will be signing three executive orders that will significantly lower prescription drug prices. Meadows did not specify the content or timing of the executive orders.
Most longevity and aging research focuses on specific genes in extremely long-lived species, but a growing body of evidence suggests "lifespan is a complex and highly context-dependent trait that calls for a shift in how biologists think about aging," writes Amanda Kowalczyk, a PhD candidate in computational and systems biology. A better approach may be to study the interaction of many genes with similar functions that impact longevity and study those genes and interactions in many species, Kowalczyk writes.